Abbvie is a general drug manufacturer company located in Illinois, United States, which is part of the Healthcare sector, and is traded under the ticker ABBV on the NYSE exchange.
Abbvie stock last closed at $227.45, up 1.85% from the previous day, and has increased 32.52% in one year. It has overperformed other stocks in the Drug Manufacturers - General industry by 0.04 percentage points. Abbvie stock is currently +38.36% from its 52-week low of $164.39, and -7.09% from its 52-week high of $244.81.
As of Dec 15, 2025, there are 1.77B shares of ABBV outstanding. The market value of ABBV is $401.99B. In the last 24 hours, 5.97M ABBV shares were traded.
You need a brokerage account in order to access the NYSE market and buy ABBV shares.
In our opinion, eToro is the best stock brokerage. Here's why:
Get $10 towards your purchase of shares by signing up for an account with eToro now. This offer is only for US users.
Open eToro AccountNow that you've selected your brokerage, it's time to fill out some personal details so you are able to invest in ABBV stock today.
Now that you have opened your account on a good stock buying app, you need to deposit funds:
Check out the walkthrough below if you need help depositing money into your brokerage account.
After you have figured out the best place to buy Abbvie stock, it's important to research their stock before you buy, so you can comprehend the risk as well as the opportunity.
WallStreetZen was created to help part-time investors perform better fundamental analysis quickly.
You can view all of the due diligence checks on ABBV's stock page.
You can use a variety of different financial metrics, analyses, models, and charts to gauge ABBV's true value.
Using relative valuations metrics:
You can access additional valuation analysis on ABBV's stock here.
Out of 14 sell side analysts who give ratings on ABBV, the consensus analyst rating on Abbvie is a Strong Buy
It's important to note that analyst ratings are not stock recommendations, nor are they investment advice.
Chris Schott, a top 15% analyst from JP Morgan maintains ABBV with a strong buy rating and raises their ABBV price target from $250.00 to $260.00, on Nov 3, 2025.
JP Morgan's Chris Schott raised their price target on Abbvie (NYSE: ABBV) by 4% from $250 to $260 on 2025/11/03. The analyst maintained their Strong Buy rating on the stock.
AbbVie reported its Q3 2025 earnings.
Schott said they updated their estimates and hiked their price target on the strength of the quarter's results.
Vamil Divan, a top 3% analyst from Guggenheim maintains ABBV with a strong buy rating and raises their ABBV price target from $227.00 to $242.00, on Oct 20, 2025.
Gary Nachman, a top 35% analyst from Raymond James reiterates ABBV with a buy rating and raises their ABBV price target from $236.00 to $250.00, on Oct 17, 2025.
Christopher Raymond, a bottom 18% analyst from Piper Sandler maintains ABBV with a strong buy rating and raises their ABBV price target from $231.00 to $284.00, on Oct 10, 2025.
Carter Gould, a top 12% analyst from Cantor Fitzgerald maintains ABBV with a strong buy rating and raises their ABBV price target from $245.00 to $250.00, on Oct 9, 2025.
You can dive deeper into what analysts are forecasting on the Abbvie stock forecast page.
Last year, ABBV earnings were $2.39B. Over the last 5 year, ABBV's earnings have grown by -22.48% per year. This was slower than the Drug Manufacturers - General industry average of 11.57%.
Last year, ABBV revenue was $59.64B. Over the past five year, ABBV's revenue has grown by 7.97% per year. This was slower than the Drug Manufacturers - General industry average of 10.94%.
Dig into ABBV's earnings and revenue performance here.
Over the last 12 months, executives and large shareholders at ABBV have sold more shares than they have bought.
Azita Salekigerhardt, EVP CHIEF OPERATIONS OFFICER of ABBV, was the latest ABBV insider to buy. They bought $2,324,418.20 worth of ABBV stock on Aug 12, 2025.
Learn more about who owns ABBV shares here.
Abbvie pays a dividend of 2.16%, compared to the Drug Manufacturers - General industry's average dividend yield of 2.71%. If you owned $1,000 worth of ABBV stock, you would have received $21.63 in the past 12 months.
Abbvie dividend payments have consistently grown over the past decade and have remained stable.
Get more info about Abbvie dividend yield and history here.
One of the primary reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to see what other community members have to say.
There are two main options:
Press the Open Trade button and your broker will place the order.
If you require additional assistance investing in stocks on eToro, click the how to video below:
Now that you own some shares in ABBV, you'll want to keep up with your investment.
Put ABBV on a watchlist to see the latest developments about your ABBV stock.
To reiterate, here are the 6 steps to buy stock in Abbvie:
If you require a place to buy stocks, eToro is our favorite option.
Get Started with eToro TodayIf you want to monitor your investment in Abbvie, create a watchlist today.